Please cite this article in press as: Halberstadt AL. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res (2014), http://dx. doi. org/10. 1016/j. bbr. 2014. 07. 016ARTICLE IN PRESSG Model BBR 9035 1-22 22 A. L. Halberstadt / Behavioural Brain Research xxx (2014) xxx-xxx [448] Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, et al. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT 2Aantagonist with a favorable CNS safety proﬁle. J Pharmacol Exp Ther 1996;277:968-81. [449] Bartoszyk GD, van Amsterdam C, Böttcher H, Seyfried CA. EMD 281014, a new selective serotonin 5-HT 2Areceptor antagonist. Eur J Pharmacol 2003;473:229-30. [450] Jennings KA, Sheward WJ, Harmar AJ, Sharp T. Evidence that genetic varia-tion in 5-HT transporter expression is linked to changes in 5-HT 2Areceptor function. Neuropharmacology 2008;54:776-83. [451] Gorzalka BB, Hill MN, Sun JC. Functional role of the endocannabinoid system and AMPA/kainate receptors in 5-HT2A receptor-mediated wet dog shakes. Eur J Pharmacol 2005;516:28-33. [452] Egashira N, Shirakawa A, Okuno R, Mishima K, Iwasaki K, Oishi R, et al. Role of endocannabinoid and glutamatergic systems in DOI-induced head-twitch response in mice. Pharmacol Biochem Behav 2011;99:52-8. [453] Rojas-Corrales MO, Gibert-Rahola J, Mico JA. Role of atypical opiates in OCD Experimental approach through the study of 5-HT(2A/C) receptor-mediated behavior. Psychopharmacology (Berl) 2007;190:221-31. [454] Marek GJ. Behavioral evidence for mu-opioid and 5-HT2A receptor interac-tions. Eur J Pharmacol 2003;474:77-83. [455] Gewirtz JC, Marek GJ. Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neu-ropsychopharmacology 2000;23:569-76. 2549 255025512552255325542555255625572558255925602561 2562256325642565256625672568256925702571